WA
KYMR icon

Wasatch Advisors’s Kymera Therapeutics KYMR Stock Holding History

Wasatch Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-572,907
Closed -$7.96M – 261
2023
Q3 		$7.96M Sell
572,907
-626,443
-52% -$12.6M 0.05% 155
2023
Q2 		$27.6M Buy
1,199,350
+161,936
+16% +$4.64M 0.17% 107
2023
Q1 		$30.7M Buy
1,037,414
+205,193
+25% +$6.62M 0.19% 99
2022
Q4 		$20.8M Sell
832,221
-228,340
-22% -$6.09M 0.14% 131
2022
Q3 		$23.1M Buy
1,060,561
+489,917
+86% +$12.9M 0.16% 122
2022
Q2 		$11.2M Buy
570,644
+333,287
+140% +$7.78M 0.07% 166
2022
Q1 		$10M Sell
237,357
-3,594
-1% -$152K 0.05% 185
2021
Q4 		$15.3M Sell
240,951
-415
-0.2% -$24.2K 0.06% 177
2021
Q3 		$14.2M Buy
241,366
+2,264
+0.9% +$131K 0.06% 191
2021
Q2 		$11.6M Buy
+239,102
New +$10.4M 0.05% 201

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors's KYMR Position: Q4 2023 in Review

Wasatch Advisors sold out of Kymera Therapeutics (KYMR) in Q4 2023, closing a stake of 572,907 shares — an estimated $7.96M sold.

Wasatch Advisors first reported a position in KYMR in Q2 2021 and held it in 10 quarters. The position peaked at $30.7M in Q1 2023. 136 funds tracked by Wall St. Rank hold KYMR as of Q4 2023.

  • Wasatch Advisors reported no remaining Kymera Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Wasatch Advisors sold 572,907 Kymera Therapeutics shares in Q4 2023, an estimated $7.96M.
  • Wasatch Advisors first reported a position in Kymera Therapeutics in Q2 2021 and held it in 10 quarters.
  • Wasatch Advisors's Kymera Therapeutics position peaked at $30.7M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2023.

Based on Wasatch Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.